1974 APPENDIX VI

LIST OF PARTICIPANTS AND PAPERS PRESENTED FOR SEMINARS

CHEMICAL CARCINOGENESIS

I. The Action of Protease Inhibitors and Carcinogenesis
	March 1975, Hawaii
U.S.A.
	1.	Walter Troll New York University	The inhibition of carcinogenesis by protease inhibitors: Assay of proteases with Protamine.
	2.	Mortimer Levitz New York University	Activation of protease and plasminogen activator by Estradiol and progesterone: Modification of hormone Action by Leupeptin and Antipain.
	3.	Laszlo Lorand Northwestern University	The cascade activation of proteases.
	4.	Edward Reich Rockefeller University	Plasminogen activator: The characteristic enzyme of cancer.
	5.	Eliot Shaw Brookhaven National Laboratory	Serine Proteases: Their action and site specific inhibitors.
	6.	Arthur Upton State University of New York at Stony Brook
	7.	Bernard Weinstein Columbia University	The mechanism of inhibition of carcinogenesis by dexamethasone: Inhibition of plasminogen activator excretion.
	8.	Lowell M. Breenbaum Columbia University	Pepstatin inhibition of neoplastic ascites fluid accumulation.
JAPAN
	1.	Takashi Sugimura National Cancer Center Research Institute	Past, present and future, Japanese cancer research using protease inhibitors.
	2.	Hamao Umezawa Institute of Microbial Chemistry	Isolation and characterization of microbial protease inhibitors.
	3.	Setsuro Fujii Tokushima University	Protease inhibitors and cellular proteases.
	4.	Takashi Kawachi National Cancer Center Research Institute	Pepstatin, Leupeptin and stomach carcinogenesis of rat.
	5.	Yoshitaka Nagai Tokyo Metropolitan Institute of Gerontology	Protease inhibitors and blast formation of lymphatic cells.
	6.	Shozo Takayama Cancer Institute	Leupeptin and liver carcinogenesis.
	7.	Takaaki Aoyagi Institute of Microbial Chemistry	Pepstatin inhibition of neoplastic ascites by SV 40 virus.
	8.	Taijiro Matsushima The University of Tokyo	Microbial protease inhibitors and metastasis.
	9.	Motonori Hoshi Hokkaido University	Effect of protease inhibitors on the fertilization of Sea Urchin.
	10.	Motoo Hozumi National Cancer Center Research Institute	Leupeptin and in vitro carcinogenesis
	11.	Tadao Kakizoe Tokyo Metropolitan Komagome Hospital	Leupeptin and bladder tumor of rats by N-Butyl-N-hydroxybutyl-nitrosamine.
	12.	Kazuko Hara The University of Tokyo	Determination of Leupeptin in serum, urine and feces of rats.

II. Evaluation of Methods of Carcinogenesis Testing in Mammals
	November 17-20, 1975, Hakone, Japan
U.S.A.
	1.	Umberto Saffiotti National Cancer Institute	Principles of bioassays and priority for selecting test chemicals: Current bioassay approaches in the United States and Japan
	2.	Richard R. Bates NCI Frederick Cancer Research Center	Principles of bioassays and priority for selecting test chemicals: General discussions on selecting test chemicals
	3.	Emmanuel Farber University of Toronto	Principles of bioassays and priority for selecting test chemicals: Mutagenicity, chromosomal aberrations, and other short tests
	4.	Peter N. Magee Middlesex Hospital Medical School	General discussions on evaluation of results: Problem of threshold
	5.	Norbert P. Page National Cancer Institute	Current bioassay approaches in the United States and Japan: Selecting test chemicals: Condition of animal care and diet: Questions to the U.S. Guidelines
	6.	Robert A. Squire National Cancer Institute	Pathology, appoaches and interpretation: Significance of histological diagnosis of tumors
	7.	John H. Weisburger Naylor Dana Institute for Disease Prevention, American Health Foundation	Mutagenicity, chromosomal aberrations, and other short tests: General discussions on evaluation of results: Problem of threshold
JAPAN
	1.	Shigeyoshi Odashima National Institute of Hygienic Sciences	Principles of bioassays and priority for selecting the test chemicals: General discussion of evaluation of results: Problem of weak carcinogens
	2.	Takashi Sugimura National Cancer Center Research Institute	Principles of bioassays and priority for selecting test chemicals
	3.	Makoto Enomoto St. Marianna University	Pathology, approaches and interpretation: Significance of histological diagnosis of tumors
	4.	Ryo Fukunishi Ehime University	Condition of animal care and diet
	5.	Yoshiyuki Hashimoto Tohoku University
	6.	Yuzo Hayashi Hatano Institute, Food and Drug Safety Research Center	Spieces and strains used: Spontaneous tumors
	7.	Iwao Hirono Gifu University	Spieces and strains used: Susceptibility
	8.	Yoshio Ikeda National Institute of Hygienic Sciences	Spieces and strains used: Susceptibility
	9.	Hidehiko Isaka Kagoshima University
	10.	Motoi Ishidate National Institute of Hygienic Sciences	Principles of bioassays and priority for selecting test chemicals: Mutagenicity, chromosomal aberrations, and other short tests
	11.	Takatoshi Ishikawa Cancer Institute
	12.	Nobuyuki Ito Nagoya City University	Dose levels frequency, duration, route, and method of administration: Pathology, approaches and interpretation: Significance of histological diagnosis of tumors
	13.	Takashi Kawachi National Cancer Center Research Institute	Mutagenicity, chromosomal aberrations, and other short tests
	14.	Akihiko Maekawa National Institute of Hygienic Sciences	Spieces and strains used: Spontaneous tumors
	15.	Taijiro Matsushima University of Tokyo	General discussions on evaluation of results: The Problem of threshold
	16.	Mutsushi Matsuyama Aichi Cancer Center Research Institute
	17.	Masahiro Nakadate National Institute of Hygienic Sciences	Principles of bioassays and priority for selecting test chemicals: General discussions on selecting test chemicals
	18.	Toshiaki Ogiu National Institute of Hygienic, Sciences	Condition of animal care and diet
	19,	Shoji Tokuoka Hiroshima University
	20.	Kenjiro Yokoro Hiroshima University	Spieces and strains used: Susceptibility

III. Modified Cellular and Molecular Controls in Neoplasia
	December 9-12, 1975, Hawaii
U.S.A.
	1.	Wayne E. Criss Howard University	Regulation by the adenylate and guanylate energy charge in neoplastic liver.
	2.	Stuart A. Aaronson National Cancer Institute	Cellular genetic controls in endogenous viral production
	3.	Henry C. Pitot, Jr. University of Wisconsin	Intercellular membranes and post-transcriptional regulation in neoplasia
	4.	Russell Hilf University of Rochester	Hormonal controls in mammary neoplasia
	5.	Francis Kenney Oak Ridge National Laboratory	Glucocorticoid regulation in cultured hepatoma cells
	6.	Nelson Goldberg University of Minnesota	Regulation of cyclic GMP and cyclic AMP
	7.	Chung Wu University of Michigan	Hormonal regulation of some enzymes in amino acid metabolism
	8.	Rameshwar K. Sharma University of Tennessee	Regulation of steroidogenesis in adrenal tumors
	9.	Marvin D. Siperstein University of California, San Francisco	Regulation of cholesterol synthesis in neoplasia
	10.	John J. Voorhees University of Michigan	Cyclic nucleotides in benign tumors
	11.	Kenneth S. McCarty Duke University	Hormonal induction of neoplasia
	12.	Philip Coffino University of California, San Francisco	Somatic genetic analysis of hormone action
	13.	Eugene DeSombre University of Chicago	Steroid receptors in breast neoplasia
	14.	George Johnson National Cancer Institute	Cyclic nucleotide regulation in normal and transformed cells
	15.	John J. Perkins University of Colorado	Regulation of CAMP in malignant brain cells
	16.	Wesley D. Wicks University of Colorado	Effects of cyclic AMP derivatives on tumor cells
	17.	A. W. Hsie Oak Ridge National Laboratory	Action of cyclic AMP in Chinese hamster ovary cells
	18.	Harris Busch Baylor College of Medicine	Nucleic acid metabolism in neoplasia
	19.	Sidney Weinhouse Temple University	Isozyme composition and gene regulation in experimental hepatomas
	20.	S. Abraham Bruce Lyon Memorial Research Laboratory, Oakland, Calif.	Lipids and lipogenesis in murine mammary neoplastic system
	21.	Arthur C. Upton State University of New York at Stony Brook
	22.	Lawrence H. Piette Cancer Center of Hawaii
	23.	J. C. Bartley University of California, Oakland
	24.	Frederick Greenwood Cancer Center of Hawaii
	25.	Tom Humpherys Cancer Center of Hawaii
JAPAN
	1.	Tetsuo Ono Cancer Institute, Japanese Foundation for Cancer Research	The mechanism of alkaline phosphatase induction in cultured mammary carcinoma cells
	2.	Takashi Sugimura National Cancer Center Research Institute	Recent advances in studies on poly (ADP Ribose)
	3.	Hiroshi Terayama The University of Tokyo	Epinephrine and corticoid receptors in plasma membranes of liver and hepatomas
	4.	Yasutomi Nishizuka Kobe University	Protein phosphokinases and mode of action of cyclic GMP
	5.	Mitsuaki Yoshida Cancer Institute, Japanese Foundation for Cancer Research	Adenylate cyclase activity in cells transformed by avian sarcoma viruses
	6.	Akira Ichihara Tokushima University	Isozymes of cultured liver cells
	7.	Shigeru Tsuiki Tohoku University	Neoplastic alterations and mechanisms of glucosamine 6-phosphate synthetase
	8.	Michihiko Kuwano Kyushu University	Regulation of RNA metabolism in malignant cells
	9.	Hiroshi Kimura Osaka University	Cyclic nucleotide in hepatoma
AUSTRALIA
	1.	John Sabine University of Adelaide	Progressive loss of cellular metabolic controls during hepatic carcinogenesis
	2.	A. W. Murray Flinders University	Effects of carcinogens and tumor promotors on epidermal cyclic nucleotide metabolism
	3.	F. J. Ballard Division of Human Nutrition, C. S. I. R. O., Adelaide	Regulation of protein degradation in cultured hepatoma cells
	4.	J. J. Marchalonis Walter and Eliza Hall Institute	Membrane immunoglobulins of neoplastic human and murine lymphocytes
	5.	J. F. Williams Australian National University	The status of pyridine and adenine nucleotide ratios and of futile substrate cycling in the regulation of the energy metabolism and proposed hyperthermic regression of neoplasms
	6.	F. L. Bygrave Australian National University	Mitochondrial calcium transport and the regulation of metabolism by calcium in tumor cells

CANCER VIROLOGY

I. Recent Advances in Tumor Virology
	March 22-23, 1975, Hawaii
U.S.A.
	1.	Robert M. McAllister Childrens Hospital of Los Angeles	RD-114 virus: a status report
	2.	Fred Rapp The Pennsylvania State University	A quantitative focus assay for transformation by Herpes simplex virus.
	3.	J. T. August Albert Einstein College of Medicine	Genetic expression of RNA tumor viruses
	4.	Robert Gallo National Cancer Institute	Primate type-C viruses and leukemia.
	5.	Walter Eckhart The Salk Institute for Biological Studies	Gene functions of polyoma virus
	6.	Murray Gardner University of Southern California	Epidemiology and virology of naturally occurring cancer in wild mice.
JAPAN
	1.	Yohei Ito Kyoto University	Shope papilloma-carcinoma complex as a prospective model for human cencer research
	2.	Hiroto Shimojo The University of Tokyo	Analysis of cell transformation with temperature mutants of Simian virus 40
	3.	Toyoro Osato Hokkaido University	Studies on the target cells for transformation by EB virus.
	4.	Kumao Toyoshima Osaka University	Temperature dependent properties of the cells transformed by ts 121, a temperature sensitive mutant of polyoma virus.
	5.	Kei Fujinaga Sapporo Medical College	Partial viral genome estimation: viral genome in adenovirus transformed cells.
	6.	Yoji Ikawa Cancer Institute	Release of differentiation arrest in Friend virus-induced leukemia cells
	7.	Hiroshi Yoshikura The University of Tokyo and Radium Institute, France	Host range determination of murine leukemia and sarcoma viruses

II. Viral Oncogenesis: Transmission, Persistence and Expression of Viral Genome.
	March 26-27, 1976, Kyoto
U.S.A.
	1.	R. M. McAllister University of Southern California and Childrens Hospital of Los Angeles	RD-114 virus: studies of the RNA of extracellular virus and the DNA of intracellular provirus.
	2.	W. Eckhart The Salk Institute for Biological Studies	Polyoma virus and SV 40: viral gene functions and growth regulation.
	3.	R. Gallo National Cancer Institute	The population of “Wolly Monkey (Simian) sarcoma viruses and type-C viruses from baboons and analyses of related viruses from man.
	4.	J. M. Bishop University of California, San Francisco	Avian tumor viruses: transforming genes in normal avian cells.
	5.	P. K. Vogt University of Southern California	Avian tumor viruses: gene physiology and gene mapping
	6.	M. Gardner University of Southern California	Murine type-C viruses: pathogenesis of lymphoma and paralysis in wild mice.
	7.	J. Maizel National Institute of Child Health, NIH	Human adenoviruses: early proteins.
JAPAN
	1.	Yohei Ito Kyoto University	Establishment of epithelial cell lines with tumorigenic capacity from nasopharynageal carcinoma tissues.
	2.	Hiroto Shimojo The University of Tokyo	Differentiation between T antigen and DNA binding protein in adenovirus 12-infected and transformed cells.
	3.	Tsutomu Miyamoto Nagasaki University	Ecology of an avian tumor virus: Genetic conversion of Rous sarcoma virus.
	4.	Masahide Ishibashi Aichi Cancer Center Research Institute	A search for virus-specific polypeptides in type 5 adenovirus-infected transformed cells.
	5.	Shiro Kato Osaka University	Studies on Marek’s lymphoma cell lines with respect to their association with expressions of avian RNA tumor viruses
	6.	Akira Hakura Osaka University	Polyoma virus: relation between viral gene functions and host cells.
	7.	Genki Kimura Tottori University	Transformation system for polyoma virus SV 40 and adenovirus 1 2 using clonal cultures of a rat cell line.
	8.	Kumao Toyoshima Osaka University	Control of chick helper factor in cells which lack natural group-specific antigen of avian leukosis.
	9.	Hiroshi Yoshikura The University of Tokyo	Possible role of chemical carcinogen in the induction of mouse endogenous C-type virus.
	10.	Toyoro Osato Hokkaido University	Type-C virus as a possible influencing factor of Epstein Barr virus expression.
	11.	Kei Fujinaga Sapporo Medical College	Viral genome in adenovirus-transformed cells.
	12.	Sadaaki Kawai The University of Tokyo	Recombination between a ts-mutant and a deletion mutant of Rous sarcoma virus.
	13.	Yorio Hinuma Kumamoto University
	14.	Hisao Uetake Kyoto University
	15.	Yoshikatsu Ozaki Shiga Medical College
	16.	Kunihiro Notake Aichi Medical College
	17.	Mitsuaki Yoshida Cancer Institute, Japanese Foundation for Cancer Research
	18.	Katsuhiko Ono Aichi Cancer Center
	19.	Akira Seto Kyoto University
	20.	Masatoshi Owada Osaka University
	21.	T. Niwa Kyoto University

CANCER IMMUNOLOGY

I. Immunotherapy of Cancer and Its Fundamental Basis
	March 13-15, 1 975, Hawaii
U.S.A.
	1.	William D. Terry National Cancer Institute
	2.	Evan M. Hersh M.D. Anderson Hospital, Univ. of Texas	Systemic use of BCG in man
	3.	E. Carmack Holmes University of California, Los Angeles	Local and systemic use of BCG in man
	4.	Albert F. LoBuglio Ohio State University	Transfer factor-characterization and immunotherapeutic trials
	5.	James F. Holland Mount Sinai Hospital	Immunotherapy with neuraminidase treated cells
	6.	Herbert J. Rapp National Cancer Institute	BCG and related products in immunotherapy of animal tumors
	7.	Steven A. Rosenberg National Cancer Institute
	8.	Tadao Aoki National Cancer Institute	Use of Strep. hemolyticus in the AKR spontaneous leukemia model
	9.	Herbert F. Oettgen Memorial Sloan-Kettering Cancer Center	Therapeutic trials with C. parvum and other immunopotentiators
	10.	Dorothy B.Windhorst National Cancer Institute
JAPAN
	1.	Yuichi Yamamura Osaka University	In vitro adjuvant effect and antitumor activity of BCG cell wall skeleton
	2.	Ichiro Azuma Osaka University
	3.	Hiroshi Kobayashi Hokkaido University	Immunotherapy of tumor by allogeneic cells
	4.	Kokichi Kikuchi Sapporo Medical College	In vitro blastogenesis and local response of lymphocytes to human autochthonous tumors
	5.	Masayasu Kitagawa Osaka University	Cellular events of immunosuppression in tumor bearing host
	6.	Tadashi Yamamoto The University of Tokyo capacity	Antitumor antibiotics carrying immunopotentiation
	7.	Tomiko Tanaka National Cancer Center Research Institute	Effect of intratumor injection of live BCG on 3-methylcholanthrene-induced tumors of primary and early transplant generation in mice

II. Immunotherapy of Cancer and Its Fundamental Basis
	March 16-20, 1976, Coronado, California
U.S.A.
	1.	William D. Terry National Cancer Institute	Immunotherapy of malignant melanoma
	2.	J. George Mt. Sinai School of Medicine	Bekesi Immunotherapy of AML
	3.	Evan M. Hersh M. D. Anderson Hospital	1. Immunotherapy of breast cancer 1. Immunopotentiation by BCG
	4.	Richard J. Hodes National Cancer Institute	In vitro studies in melanoma patients receiving immunotherapy
	5.	Albert LoBuglio Ohio State University Hospital	Can non-specific immunotherapy affect human monocyte macrophage function ?
	6.	Donald Morton California University	Immunotherapy of melanoma and sarcoma
	7.	Herbert F. Oettgen Memorial Sloan-Kettering Cancer Center	Lysolecithin analogues as immunotherapeutic agents. Endotoxin-induced tumor necrosis factor
	8.	Herbert J. Rapp National Cancer Institute	Immunotherapy of experimental cancer with BCG
	9.	Steven A. Rosenberg National Cancer Institute	Immunologic studies on patients with sarcoma and melanoma
	10.	Dorothy B. Windhorst National Cancer Institute
JAPAN
	1.	Yuichi Yamamura Osaka University	Immunological and antitumor activities of Nocardia cell wall skeleton and synthetic peptidoglycan subunits
	2.	Kazumasa Yamada Nagoya University	Therapy of patients with acute leukemia-immunotherapy with cell wall skeleton of BCG and chemotherapy
	3.	Susumu Kishimoto Kumamoto University	Immunotherapy of leukemia with BCG cell wall skeleton
	4.	Kosei Yasumoto Kyushu Cancer Center	Immunotherapy of human lung cancer with BCG cell wall skeleton
	5.	Yoshiyuki Hashimoto Tohoku University	An approach to immunotherapy of urinary bladder cancer
	6.	Takato O. Yoshida Hamamatsu University Medical School	Tumor-specific immune response and immuno-deficiency during development of autochthonous tumor
	7.	Kokichi Kikuchi Sapporo Medical College	Role of T-cells in resistance against autochthonous tumors
	8.	Hiroshi Kobayashi Hokkaido University	Xenogenization and its application to immunotherapy of cancer
	9.	Masayasu Kitagawa Osaka University	T cell functions in resistance against cancer

CANCER CHEMOTHERAPY

I. Comparative Study on Cytosine Arabinoside and Cyclocytidine, Experimental and Clinical
	February 13-14, 1975, Tokyo
U.S.A.
	1.	Stephen K. Carter National Cancer Institute	Cytosine Arabinoside and Cyclocytidine as an example of the problem in analogue development. An overview of the U.S. experience with Ara-C.
	2.	Abraham Goldin National Cancer Institute	Cytosine Arabinoside and Cyclocytidine as example of the problem of schedule dependence testing. Combination experimental studies with Cytosine Arabinoside and Cyclocytidine
	3.	Kenneth B. McCredie M. D. Anderson Hospital, University of Texas	Clinical experience with Cyclocytidine in the U.S. Cytosine Arabinoside alone and in combination in the treatment of acute adult leukemia
	4.	Dah H. Ho M.D. Anderson Hospital, University of Texas	Pharmacologic studies with cyclocytidine in the U.S.
	5.	Irwin H. Krakoff Memorial Sloan-Kettering Cancer Center	Development of and clinical experience with AAFC a fluorinated analogue of cyclocytidine
JAPAN
	1.	Yoshio Sakurai Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
	2.	Susumu Hibino National Nagoya Hospital
	3.	Hachihiko Hirayama Kohjin Co., Ltd.
	4.	Akio Hoshi National Cancer Center Research Institute	Metabolism of cyclocytidine
	5.	Akira Hoshino Cancer Chemotherapy Center, Japanese Foundation for Cancer Research	On the basis of experimental combination chemotherapy
	6.	Motonobu Ichino Kojin Co., Ltd.	Pharmacology of cyclocytidine
	7.	Touru Ise National Cancer Center Hospital	Clinical effects of cyclocytidine in the treatment of acute leukemia in children
	8.	Kiyoji Kimura National Cancer Center Hospital	Cytocidal action of cyclocytidine in comparison of that of cytosine arabinoside. An overview of the clinical effects of cyclocytidine in the treatment of acute leukemia in Japan. The 6th National Hospital controlled cooperative studies of clinical effects of cyclocytidine alone and in combination in the treatment of acute leukemia
	9.	Kazuo Kuretani National Cancer Center Research Institute	Metabolism of cyclocytidine
	10.	Toru Masaoka Center for Adult Diseases, Osaka	On the decrease curve of leukemic cell in the treatment of acute leukemia with special reference to that of cyclocytidine
	11.	Toru Nakamura Kyoto University	Mechanism of action of cyclocytidine in comparison of that of cytosine arabinoside
	12.	Makoto Ogawa Aichi Cancer Center	Clinical effect of combination chemotherapy including cytosine arabinoside in the treatment of acute leukemia
	13.	Ryuzo Ohno Nagoya University	Clinical effect of combination chemotherapy including cyclocytidine in the treatment of acute leukemia
	14.	Kazuo Oota Aichi Cancer Center	Clinical effect of combination chemotherapy including cytosine arabinoside in the treatment of acute leukemia
	15.	Hiroshi Otsuki National Cancer Center Hospital	Clinical effects of cyclocytidine in the treatment of acute leukemia in children
	16.	Yasunobu Sakai National Cancer Center Hospital	Trial of new administration method of cyclocytidine and its clinical effects
	17.	Teruo Sakano National Cancer Center Hospital	Trial of new administration method of cyclocytidine and its clinical effects
	18.	Nobuyuki Senda Center for Adult Diseases, Osaka	On the decrease curve of leukemic cell in the treatment of acute leukemia with special reference to that of cyclocytidine
	19.	Shigeru Tsukagoshi Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
	20.	Hamao Umezawa Institute of Microbial Chemistry
	21.	Gyoichi Wakisaka Kyoto University	Mechanism of action of cyclocytidine in comparison of that of cytosine arabinoside
	22.	Kazumasa Yamada Nagoya University	Clinical effect of combination chemotherapy including cyclocytidine in the treatment of acute leukemia

II. Phase I Study
	February 14-15, 1975, Tokyo
U.S.A.
	1.	Stephen K. Carter National Cancer Institute	NCI approach to clinical drug testing
	2.	Abraham Goldin National Cancer Institute	The potential impact of experimental studies on the clinic
	3.	Kenneth B. McCredie M. D. Anderson Hospital, University of Texas	Principles of Phase I Study evaluation
	4.	Dah H. Ho M. D. Anderson Hospital, University of Texas	The interaction of the pharmacologist in clinical drug evaluation
	5.	Irwin H. Krakoff Memorial Sloan-Kettering Cancer Center	Principles of Phase II Study evaluation
JAPAN
	1.	Yoshio Sakurai Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
	2.	Ichita Amaki Nihon University
	3.	Hiroshi Fujita Tsurumi University	Pharmacokinetics of anticancer agents for a clinical application
	4.	Hisashi Furue Cancer Institute Hospital, Japanese Foundation for Cancer Research
	5.	Yoshio Hara Niigata Cancer Center
	6.	Takao Hattori Hiroshima University
	7.	Akira Hoshino Cancer Chemotherapy Center, Japanese Foundation for Cancer Research	Evaluation of anticancer agents using L1210 mouse leukemia. Phase I study of methyl-CCNU in Japan
	8.	Munemoto Ito The Second National Hospital of Tokyo
	9.	Kiyoji Kimura National Cancer Center Hospital	The in vitro screening and evaluation of anticancer agents. Phase I study of ACNU 3-[(4-amino-2-methyl-5 pyrimidiny) methyl] -1-(2-chloroethyl)-I -nitrosourea hydrochloride
	10.	Tatsuhei Kondo Nagoya University
	11.	Yoshiyuki Koyama National Medical Center Hospital	Phase III Study of stomach cancer at National Hospital Chemotherapy Groups
	12.	Tadashi Maekawa Gunma University
	13.	Hisashi Majima Chiba Cancer Center
	14.	Hiroaki Nakazto Aichi Cancer Center	Effects of mitomycin C as an adjuvant chemotherapy for the curative operation of stomach cancer (Phase III study)
	15.	Hisanobu Niitani National Cancer Center Hospital
	16.	Kazuo Oota Aichi Cancer Center
	17.	Tatsuo Saito Tohoku University
	18.	Hiroshi Sato Sasaki Institute	Tumor spectrum of new anticancer agents using ascites hepatoma in rats
	19.	Nobuyuki Senda Center for Adult Diseases, Osaka
	20.	Tetsuo Taguchi Osaka University
	21.	Fujimaro Takaku Jichi Medical School
	22.	Shigeru Tsukagoshi Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
	23.	Masanori Shimoyama National Cancer Center Hospital	The in vitro screening and evaluation of anticancer agents
	24.	Hamao Umezawa Institute of Microbial Chemistry
	25.	Gyoichi Wakisaka Kyoto University
	26.	Yasunobu Sakai National Cancer Center Hospital	Phase I Study of ACNU 3-[(4-amino-2-methyl-5 pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride
	27.	Kazumasa Yamada Nagoya University
	28.	Kazuo Yunoki Kagoshima University

III. Diagnosis and Treatment of Gastric Cancer
	December 9, 1975, Tokyo
U.S.A.
	1.	Stephen K. Carter National Cancer Institute	The current approach to gastrointestinal cancer therapy
	2.	Harry Handelman National Cancer Institute	Review of other studies in gastric cancer
	3.	Edward D. Holyoke State University of New York at Buffalo	Surgery of gastric cancer
	4.	Philip T.Lavin State University of New York, Amherst	The role of the statistician in clinical trials with special emphasis on gastrointestinal cancer
	5.	Charles G. Moertel University of Minnesota	Chemotherapy of gastric cancer
	6.	Philip S. Schein Georgetown University	The gastrointestinal tumor study group -Structure and gastric cancer protocols
JAPAN
	1.	Yoshio Sakurai Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
	2.	Tamaki Kajitani Cancer Institute Hospital, Japanese Foundation for Cancer Research	The present status of surgical role in treatment of gastric cancer in Cancer Institute
	3.	Kiyoji Kimura National Cancer Center Hospital
	4.	Toshio Kurokawa Cancer Institute Hospital, Japanese Foundation for Cancer Research
	5.	Hisashi Majima Chiba Cancer Center
	6.	Kiyoshi Miwa National Cancer Center Hospital	Statistical data of more than 10,000 stomach cancer patients treated in Japan
	7.	Toshifusa Nakajima Cancer Institute Hospital, Japanese Foundation for Cancer Research
	8.	Kyoichi Nakamura Tsukuba University	Diagnosis of early stomach cancer -Biopsy-
	9.	Hiroaki Nakazato Aichi Cancer Center	Some additional presentations on the statistical investigation
	10.	Yanao Ogura National Cancer Center Hospital
	11.	Tatsuo Saito Tohoku University	The methods and results of chemotherapeutic treatment of gastric cancer by the protocols
	12.	Takao Sakita Tsukuba University	Diagnosis of early stomach cancer -Endoscopy-
	13.	Hikoo Shirakabe Juntendo University	Diagnosis of early stomach cancer -X-ray diagnosis-
	14.	Haruo Sugano Cancer Institute, Japanese Foundation for Cancer Research
	15.	Takao Takekoshi Cancer Institute Hospital, Japanese Foundation for Cancer Research	Diagnosis of early stomach cancer -Biopsy-
	16.	Shigeru Tsukagoshi Cancer Chemotherapy Center, Japanese Foundation for Cancer Research
	17.	Hamao Umezawa Institute of Microbial Chemistry
	18.	Teruo Sakano National Cancer Center Hospital

IV. Comparative Studies of New Antitumor Agents and New Modality of Application - Symposium on the Nitrosoureas, Symposium on Bleomycin –
	February 6-8, 1976, Hawaii
U.S.A.
	1.	Stephen K. Carter National Cancer Institute	The Nitrosoureas-thoughts for the future-An overview of Bleomycin in U.S. clinical trials
	2.	Abraham Goldin National Cancer Institute	Experimental studies with Bleomycin and their implication for clinical trial
	3.	Irwin Krakoff Memorial Solan-Kettering Cancer Center	Studies with the Nitrosoureas at Memorial Hospital Bleomycin studies at the Memorial Sloan-Kettering Cancer Center
	4.	Robert Livingston M.D. Anderson Hospital and Tumor Institute University of Texas	Combination chemotherapy approaches with the Nitrosoureas Bleomycin in combination chemotherapy regimens for solid tumors
	5.	Frank M. Schabel, Jr. Southern Research Institute	Experimental tumor data with the Nitrosoureas and the implications for future analogue development
	6.	Philip Schein Vincent T. Lombardi Cancer Research Center Gerogetown University	Streptozotocin - Current status and background and new analogues
	7.	Todd Wasserman National Cancer Institute	An overview of the Nitrosoureas in U.S. clinical trials (BCNU, CCNU, MeCCNU) Bleomycin in combination chemotherapy Regimens for the malignant lymphomas
JAPAN
	1.	Yoshio Sakurai Cancer Chemotherapy Center; Japanese Foundation for Cancer Research	Introduction of GANU
	2.	Ikuichiro Hiroto Kyushu University	The effect of Bleomycin on the head and neck tumors
	3.	Tokuji Ichikawa Tokyo University	Simultaneous combination with Bleomycin and radiation in the cancer therapy
	4.	Kaichi Isono University of Chiba	Studies on the combined therapy with Bleornycin and radiation for esophageal carcinoma
	5.	Tatuo Saito Tohoku University	An overview of Phase 11 Study of ACNU
	6.	Teruo Sakano National Cancer Center Hospital	An overview of Phase I Study of ACNU
	7.	Yasushi Shigematsu Osaka University	Present state of a controlled study of combined treatment with Bleomycin and radiation in Kyoto-Osaka-Kobe Area
	8.	Toyozo Terashima National Institute of Radiological Sciences	Effect of Bleomycin on mammalian cells- The implication for tumor therapy
	9.	Hamao Umezawa Institute of Microbial Chemistry
	10.	Masao Arakawa Sankyo Pharmaceutical Co., Ltd.	Pharamacology of ACNU
	11.	Akira Matsuda Nippon Kayaku Co.	Experimental chemotherapy of rat stomach cancer with Bleomycin

ANALYTICAL EPIDEMIOLOGY

I. Analytical Epidemiology of Cancer
	December 2-5, 1 975, Orlando, Florida
U.S.A.
	1.	Robert W. Miller National Cancer Institute
	2.	W. J. Schull University of Texas
	3.	H. T. Lynch Creighton University
	4.	A. M. DiGeorge St. Christopher’s Hospital for Children, Philadelphia
	5.	J. J. Mulvihill National Cancer Institute
	6.	J. F. Fraumeni National Cancer Institute
	7.	W. E. Heston National Cancer Institute
JAPAN
	1.	Takeshi Hirayama National Cancer Center Research Institute	New horizon in cancer epidemiology
	2.	Noboru Kobayashi The University of Tokyo	Precious cases in the epidemiology of childhood malignancies in Japan.
	3.	J. Utsunomiya Tokyo Medical-Dental University	Approach to control familial polyposis in Japan. Gastric lesion in familial polyposis
	4.	M. Hitosugi Kitasato University	New understanding of occupational cancer problems in Japan
	5.	K. Mabuchi Johns Hopkins School of Public Health	An occupational study in progress
	6.	T. Yoshimura Kyushu University	Epidemiological approach to PCB problems in Japan
	7.	K. Fukuda Sapporo Medical College	Methodology in analytical epidemiology

LUNG CANCER

I. The Meeting for Morphology and Staging of Lung Cancer
	March 26-28, 1975, Tokyo
U.S.A.
	1.	Clifton F. Mountain M.D. Anderson Hospital and Tumor Institute University of Texas	Correlation between T. N M. to Prognosis Correlation between Primary Variables of Staging to Survival
	2.	Mary Mattews National Cancer Institute	Histological Classification in U.S.A. Selected Problems in Histology
JAPAN
	1.	Takeshi Hirayama National Cancer Center Research Institute
	2.	Shichiro Ishikawa National Cancer Center Hospital	Uniformity of T.N.M. classification between American and Japan Joint Committee
	3.	Yukio Shimosato National Cancer Center Hospital	Histological classification by N.C.C.
	4.	Toshio Kitagawa National Cancer Center Hospital	Radiotherapy
	5.	Hisanobu Niitani National Cancer Center Hospital
	6.	Keiichi Suemasu National Cancer Center Hospital	Co-ordinate staging carrying out at M.H. and N.C.C.
	7.	Yoshihiro Hayata Tokyo Medical College	Surgical adjuvant chemotherapy
	8.	Shoji Hattori Center for Adult Diseases, Osaka	E.M. findings of oat cell carcinoma chemotherapy
	9.	Yutaka Hayashi Chiba University
	10.	Yutaka Yamaguchi Chiba University	Surgical adjuvant chemotherapy
	11.	Yoshio Okada Aichi Cancer Center	Surgical adjuvant chemotherapy
	12.	Iwao Kinoshita Cancer Institute, Japanese Foundation for Cancer Research	Surgical adjuvant chemotherapy
	13.	Hiomi Homma Juntendo University	Staging by J.L.C.S. chemotherapy

II. The Meeting for Detection of Early Lung Cancer
	November 25-26, 1975, Tokyo
U.S.A.
	1.	Robert S. Fontana Mayo Clinic	Mayo Lung Project and N.C.I. Project case presentation of early lung cancer - U.S. cases-
	2.	Morton L. Levin Johns Hopkins University	Epidemiology in U.S. (Lung Cancer)
	3.	Geno Saccomanno St. Mary’s Hospital	Cytology of sputum prior to the development of lung cancer
	4.	David R.Sanderson Mayo Clinic	Current status of bronchoscopic findings of early lung cancer and newer development of bronchoscopic examination and endoscopic localization of early lung cancer
	5.	Lewis B. Woolner Methodist Hospital and Mayo Clinic	Case presentation of early lung cancer -U.S. cases. Cytopathologic aspects of early lung cancer
JAPAN
	1.	Takeshi Hirayama National Cancer Center Research Institute	Epidemiology in Japan
	2.	Shigeto Ikeda National Cancer Center Hospital	Japanese Lung Cancer Project for early detection Current status of bronchoscopic findings of early lung cancer
	3.	Shoji Hattori Center for Adult Diseases, Osaka	Cytopathologic aspects of early lung cancer Difference between exfoliated cancer cells and well preserved cancer cells
	4.	Yoshihiro Hayata Tokyo Medical College	Japanese Lung Cancer Project for therapy
	5.	Hiomi Honma Juntendo Medical College
	6.	Shihei Horie Dokkyo University	New technique for the examination of bronchoscopy
	7.	Iwao Kinoshita Cancer Institute Hospital, Japanese Foundation for Cancer Research
	8.	Yuzuru Nishimura Aichi Cancer Center	Case presentation of peripheral early lung cancer
	9.	Yukio Shimozato National Cancer Center Hospital	Case presentation of early lung cancer Japanese cases - pathological report
	10.	Masanobu Takahashi Kyorin Medical University	Cytology in early lung cancer of central type
	11.	Takashi Teramatsu Kyoto University	Case presentation of early lung cancer
	12.	Hiroshi Yoshimatsu Kitazato Institute Hospital	Japanese mediastinal diagnosis project

BREAST CANCER

I. Breast Cancer Planning Seminar
	July 15-19, 1974, Bethesda, Maryland
U.S.A.
	1.	Nathaniel I. Berlin National Cancer Institute
	2.	Gregory T. O’Conor National Cancer Institute
	3.	Paul P. Carbone National Cancer Institute
	4.	William McGuire University of Texas, San Antonio
JAPAN
	1.	Haruo Sugano Cancer Institute, Japanese Foundation for Cancer Research
	2.	Yoji Ikawa Cancer Institute, Japanese Foundation for Cancer Research
	3.	Keijiro Kuno Cancer Institute Hospital, Japanese Foundation for Cancer Research

II. U.S.-Japan Joint Seminar on Breast Cancer - Focusing Binational Efforts on Breast Cancer -
	March 26-27, 1976, Tokyo
U.S.A.
	1.	Nathaniel I. Berlin Northwestern University	The Breast Cancer Task Force of the National Cancer Institute - History and Development
	2.	William L. McGuire University of Texas	Progesteron receptor of breast cancer and its correlation with clinical response
	3.	Guy R. Newell, Jr. National Cancer Institute	Simultaneous occurrence of breast and other cancers
	4.	Robert R. Omata National Cancer Institute
	5.	William Pomerance National Cancer Institute	The possible contribution and limitations of the detection of early lesions to survival from breast cancer
	6.	Pietro M.Gullino National Cancer Institute	Mammary tumor regression after hormonal deprivation of the host
	7.	Paul P. Carbone National Cancer Institute	Changing roles of surgery, radiotherapy and chemotherapy in the treatment of primary breast cancer
	8.	Jeffrey Schlom National Cancer Institute	Structural studies of the Mason - Pfizer Monkey viruses (tentative)
	9.	David Colcher Meloy Laboratories, Inc.
	10.	Don Fine NCI Frederick Cancer Research Center
JAPAN
	1.	Haruo Sugano Cancer Institute, Japanese Foundation for Cancer Research	Histological features of breast cancer among Japanese female
	2.	Masao Fujimori Saitama Cancer Center	Activities of Japanese Mammary Cancer Society
	3.	Takeshi Hirayama National Cancer Center Research Institute	Socio-economical factors on breast cancer incidence
	4.	Yoji Ikawa Cancer Institute, Japanese Foundation for Cancer Research
	5.	Masaru Izuo Gunma University	Breast cancer cases in Japan - stage, treatment and the results
	6.	Soichi Kumaoka National Cancer Center Research Institute	Possible etiological factors in breast cancer patients - analysis of hormones
	7.	Keijiro Kuno Cancer Institute Hospital, Japanese Foundation for Cancer Research	Surgery of breast-cancer cases in Cancer Institute Hospital
	8.	Keishi Matsumoto Osaka University	Estrogen receptors on breast cancer cells
	9.	Akio Matsuzawa University of Tokyo	Pregnancy dependent virus-induced mammary tumor in DDD mice
	10.	Yasuaki Nishizuka Aichi Cancer Center Research Institute	Experimental study of mammary cancer
	11.	Harutaka Tanaka Kyoto University	Polypeptides and antigens of A and B particles of MTV
	12.	Shu Yuasa The Institute of Public Health	Breast cancer incidence and menstruating period
	13.	Osahiko Abe Keio University
	14.	Munemitsu Hoshino Aichi Cancer Center Research Institute
	15.	Tamaki Kajitani Cancer Institute Hospital, Japanese Foundation for Cancer Research
	16.	Junzo Kato Teikyo University
	17.	Noboru Kurihara Hiroshima University
	18.	Sotokichi Morii Kansai Medical University
	19.	Nobuaki Sasano Tohoku University
	20.	Eiichi Sato Kagoshima University
	21.	Osamu Takatani National Cancer Center Hospital
	22.	Hiroki Koyama Center for Adult Diseases, Osaka
	23.	Hiroshi Yamamoto National Cancer Center Hospital
	24.	Toshio Wagai Juntendo University	A new echographic apparatus for mass-screening of breast cancer

URINARY BLADDER CANCER

I. Planning Seminar of Urinary Bladder Cancer
	February 5-22, 1975, Madison, Wisconsin
U.S.A.
	1.	George T. Bryan University of Wisconsin
	2.	Ryoichi Oyasu Northwestern University
	3.	Walter Troll New York University
	4.	Gilbert Friedell St. Vincent Hospital
	5.	Joseph Leighton The Medical College of Pennsylvania
JAPAN
	1.	O. Yoshida Kyoto University
	2.	M. Okada Tokyo Biochemical Research Institute
	3.	N. Ito Nagoya City University

II. Experimental Models for Bladder Cancer
	December 7-9, 1975, Hawaii
U.S.A.
	1.	George T. Bryan University of Wisconsin
	2.	Ryoichi Oyasu Northwestern University	Urinary bladder carcinogenesis in hamsters
	3.	Gilbert Friedell St. Vincent Hospital
	4.	Joseph Leighton The Medical College of Pennsylvania	Growth of normal and malignant bladder epithelium in vitro and as heterotopic implants
	5.	S. Cohen	Bladder cancer induced by FANFT
	6.	A. M. Pamukcu University of Wisconsin	Bladder cancer in cattle and rats induced by bracken fern
	7.	C. Irving VA Hospital Memphis	Biochemical mechanisms in experimental bladder cancer
	8.	R. E. Greenfield St. Vincent Hospital	Review of other experimental studies in urinary bladder cancer in United States
	9.	M. S. Soloway	Bladder cancer in mice induced by FANFT
JAPAN
	1.	Osamu Yoshida Kyoto University	Bladder cancer in rodents following intravesical foreign body implants relevance of experimental bladder carcinogenesis studies to humans
	2.	Nobuyuki Ito Nagoya City University	Morphologic alterations of rodent urinary bladder by BBN Review of other experimental studies in urinary bladder cancer in Japan
	3.	Masashi Okada Tokyo Biochemical Research Institute	Rat urinary bladder cancer induced by butylhydroxybutylnitro samine (BBN)
	4.	Yoshiyuki Hashimoto Tohoku University	In vitro bladder carcinogenesis
	5.	Hisashi Otsuka Tokushima University	Bladder cancer in mice following BBN - cytoxan
	6.	Eigoro Okajima Nara Medical University	Bladder cancer in dogs caused by BBN

HIGH LET RADIATION THERAPY

I. High LET Radiation Therapy Planning Seminar
	August 16-18, 1975, Tokyo, Japan
U.S.A.
	1.	Glenn E. Sheline National Cancer Institute
	2.	Francis J. Mahoney National Cancer Institute	An overview of the U.S. National Cancer Institute high LET radiation therapy program
	3.	Herbert Attix U.S. Naval Research Laboratory	The physics and doshnetry of fast neutrons for radiotherapy
	4.	Rodney Withers M.D. Anderson Hospital	Radiobiology relevant to neutron radiotherapy
	5.	Robert Parker University of Washington	The current status of fast neutron teletherapy of cancer in the United States
	6.	Gunter Seydel American Oncologic Hospital	The clinical use of ²⁵² -Californium sources and ²⁵² -Californium Protocol (RTOG)
JAPAN
	1.	Akira Tsuya Cancer Institute Hospital, Japanese Foundation for Cancer Research	Clinical experiences of Californium-252 therapy
	2.	Yoichiro Umegaki National Institute of Radiological Sciences	Fast neutron therapy at NIRS Hospital Proposal for the clinical trial of the fast neutron therapy in Japan
	3.	Tetsuji Nishikawa National Laboratory of High Energy Physics	General status of accelerators in Japan possibly used for neutron applications The KEK proton synchrotron and possibility of utilizing its booster beam for high LET radiation therapy
	4.	Tetsuo Inada National Institute of Radiological Sciences	NIRS cyclotron facilities NIRS proton therapy project
	5.	Akira Ito Tokyo University Institute of Medical Sciences	TIMS cyclotron facilities The fast neutron beam from the TIMS cyclotron
	6.	Hiroshi Hatanaka Teikyo University	Slow neutron capture therapy
	7.	Haruma Yoshinaga Kyushu University	Comparative studies on the effect of 14 MeV neutrons and X-rays on cultured mammalian cells (read by H. Sasaki)
	8.	Kiyohiko Sakamoto University of Tokyo
	9.	Shigefumi Okada University of Tokyo	Some comments on the radiobiological aspects of of high LET radiation therapy
	10.	Hiroshi Tsunemoto National Institute of Radiological Sciences	Role of fractionation in fast neutron therapy Preliminary clinical trial with 2 MeV fast neutrons
	11.	Muneyasu Urano National Institute of Radiological Sciences	Repair of potentially lethal radiation damage in animal tumors in vivo
	12.	Katsuhiro Kawashima National Institute of Radiological Sciences	Neutron dosimetry in Japan
	13.	Akira Matsuyama Institute of Physical and Chemical research	Studies on LET effects on different biological systems using charged particles accelerated in the IPCR cyclotron
	14.	Hisao Yamashita Keio University	Preliminary studies on a remotely controlled afterloading equipment using high intensity sources of Californium-252
	15.	Hiroshi Iino Institute of Medical Sciences, University of Tokyo
	16.	Koichi Kaneta Cancer Institute Hospital, Japanese Foundation for Cancer Research	Clinical experiences with Californium-252 small sources
	17.	Yoshio Onai Cancer Institute, Japanese Foundation for Cancer Research
	18.	Hiroshi Sasaki Kyushu University
	19.	Eisei Tasaki Tokyo Womens Medical College
	20.	Sinichi Okuyama Tohoku University
	21.	Toshio Kitagawa National Cancer Center Hospital
	22.	Hideo Niibe Gunma University
	23.	Shozo Suzuki Institute of Medical Sciences, University of Tokyo
	24.	Akiyoshi Kumazawa Institute of Medical Sciences, University of Tokyo
	25.	Atuko Heshiki Gunma University

CYTOLOGY

I. Automation of Cancer Cytology
	February 20-21, 1975, Tokyo
U.S.A.
	1.	R. A. Malmgren George Washington University	Overview of cytology automation
	2.	C. Herman National Cancer Institute	Application of zero resolution flow analysis and sorters to cytology automation - Part I.
	3.	M. Melamed Memorial Hospital for Cancer and Allied Diseases	Application of zero resolution flow analysis and sorters to cytology automation - Part II
	4.	J. Prewitt National Institutes of Health	One score and four years of high resolution cytology automation
	5.	L. Wheeless University of Rochester	Slit scan cytofluorometry as basis for an automated prescreening system
JAPAN
	1.	K. Kimura National Cancer Center Hospital
	2.	S. Hattori Center for Adult Diseases, Osaka	Soft ware of autoscreening system
	3.	Y.Hashimoto College of Medical Technology Kansai	Hard ware of autoscreening system
	4.	Y. Kishigami Center for Adult Diseases, Osaka	Soft ware of autoscreening system
	5.	I. Nishiya Hokkaido University	Spectrophotometrical evaluation with prescreening scanning device utilizing glass fiber
	6.	I. Sawaragi Kansai Medical University	Trials on autocytoscreener
	7.	M.Tajima National Cancer Center	The results of mass screening of breast cancer
	8.	N. Tanaka Chiba Cancer Center	Field test of automated cytoscreening system (Cybest)
	9.	Y.Tenjin Kyoundo Hospital	Prescreening device utilizing 16mm roll film
	10.	Y. Uei National Cancer Center Hospital	An attempt for automatic screening in uterin cancer cytology

II. Cancer Cytology
	June 16-17, 1975, San Francisco, California
U.S.A.
	1.	R. A. Malmgren George Washington University
	2.	P. Bartels University of Arizona	Automated cytology - slide system (tentative)
	3.	W. Frable Medical College of Virginia	Aspiration cytology
	4.	Chester Herman National Cancer Institute
	5.	E. King University of California	Specimen collection for automated cytology
	6.	M. Melamed Memorial Hospital for Cancer and Allied Diseases	Investigative cytology - new fields
	7.	W. Pomerance National Cancer Institute
	8.	J. Prewitt National Cancer Institute	Computer program control for automatic cell identification and specimen classification
	9.	L. Wheeless University of Rochester	Specimen preparation for automated cytology
	10.	J. Baccus St. Luke’s Hospital	System evaluation and field testing
	11.	M.J. Fulwyler Particle Technology, Inc.	Automated cytology - flow systems
JAPAN
	1.	K. Kimura National Cancer Center Hospital	Investigative cytology using necleolar staining
	2.	Y. Hashimoto College of Medical Technology Kansai	Autoscreener - slide system
	3.	S. Hattori Center for Adult Diseases, Osaka	Specimen collection and field testing by autoscreener
	4.	M. Onoe University of Tokyo	Automated on-line microscope
	5.	I. Sawaragi Kansai Medical University	Cell identification on automated cytoscreening systems
	6.	M. Takahashi Central Hospital, Japanese National Railway	Preparation of cervical specimen for cytology automation A new approach to evaluate malignant cellular changes
	7.	N. Tanaka Chiba Cancer Center	System evaluation and field testing on cybest
	8.	Y. Tenjin Kyoundo Hospital	Cell fixation method on 16mm polyester film Population screening by selfirrigation method

METASTASIS

I. Survey Seminar on Metastasis
	March 4-11, 1975, Bethesda, Maryland
U.S.A.
	1.	Isaiah J. Fidler University of Pennsylvania
	2.	Bernard Fisher University of Pittsburgh
	3.	Pietro M. Gullino National Cancer Institute
	4.	Robert R. Omata National Cancer Institute
	5.	Philip G. Stansly National Cancer Institute
JAPAN
	1.	Haruo Sato Tohoku University
	2.	Eiro Tsubura Tokushima University